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Abstract
Background: Interferon regulatory factor (IRF) family members have been implicated as critical transcription factors that
function in immune response, hematopoietic differentiation and cell growth regulation. Activation of IRF-5 results in the
production of pro-inflammatory cytokines such as TNFa, IL6 and IL12p40, as well as type I interferons.
Methodology/Principal Findings: In this study, we identify a G202C (position relative to translation start codon) missense-
mutation transcript of IRF-5 in transformed B and T cell lines, which were either infected or non-infected by viruses, and
peripheral blood from ATL or CLL patients. The mutated transcript encodes a novel protein in which the sixty-eighth amino
acid, Alanine, is substituted by Proline (IRF-5P68) in the DNA binding domain of IRF-5. IRF-5P68 phenotype results in a
complete loss of its DNA-binding activity and functions as a dominant negative molecule through interacting with wild type
IRF-5. Co-expression of IRF-5P68 inhibits MyD88-mediated IRF-5 transactivation. Moreover, Toll-like receptor (TLR)-
dependent IL6 and IL12P40 production induced by lipopolysaccharide (LPS), R837 or CpG ODN 1826 was reduced in IRF-5
(P68) expressing cells as compared to the control cells.
Conclusion: IRF-5P68 acts as a dominant negative regulator that interferes with IRF-5-mediated production of pro-
inflammatory cytokines. The functional characterization of the novel IRF-5 mutant in transformed B and T cell lines and in
ATL and CLL patients may lead to a better understanding of the role of these transcriptional regulators in hematopoietic
malignancies.
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Introduction
Biochemical, molecular biological and gene knockout studies
have demonstrated that the members of the interferon regulatory
factor family play important roles in pathogen response, cytokine
signalling, hematopoietic differentiation, regulation of cell cycle and
apoptosis (reviewed in [1,2]. IRF-5 is involved in various activities,
including activation of type I interferon and inflammatory cytokine
gene expression and regulation of cell growth and apoptosis
[3,4,5,6]. Expression of IRF-5 has been detected in B cells and
dendritic cells, and is further enhanced by type I IFN or the tumor
suppressor p53 [7,8,9]. Two nuclear localization signals (NLS) have
been identified in IRF-5, both of which are sufficient for nuclear
translocation and retention in virus infected cells [8]. We have
demonstrated that a CRM1-dependent nuclear export pathway is
involved in the regulation of IRF-5 subcellular localization. IRF-5
possesses a functional nuclear export signal (NES) that controls
dynamic shuttling between the cytoplasm and the nucleus. The
NES element is dominant in unstimulated cells and results in the
predominant cytoplasmic localization of IRF-5 [10].
Among the IRF family members, IRF-5 and IRF-7 share the
same signaling pathway that is initiated through TLR7/8 and
TLR9 [5,11]. In response to TLR7/8 or TLR9 ligand, IRF-5
and IRF-7 are recruited to myeloid differentiation primary
response gene (MyD) 88. Unlike IRF-7, which binds the death
domain of MyD88, IRF-5 interacts with the intermediary domain
and part of the TIR domain of MyD88 [12]. The MyD88-bound
IRF-5 is activated by TNF receptor-associated factor (TRAF) 6
by an as-yet-unknown mechanism. A recent study demonstrated
that IRF-5 is subject to TRAF6-mediated K63-linked ubiquitina-
tion [13]. Activated IRF-5 translocates to the nucleus, binds to
the ISRE motifs in the promoter sequences and results in the
production of pro-inflammatory cytokines such as TNFa, IL6 and
IL12p40, as well as type I IFNs [5,11]. IRF-5 knockout mice
showed resistance to lethal shock induced by either unmethylated
DNA or lipopolysaccharide, which correlates with a marked
decrease in the serum levels of proinflammatory cytokines, and
thus identifies IRF-5 as a key player in the TLR-Myd88 signaling
pathway [5].
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that IRF-5 plays an important role in type I IFN production in a
stimulation specific and cell type dependent manner [3,4]. The
induction of type I IFNs by various TLR ligands is normal in
hematopoietic cells from IRF-5 deficient mice [5]. However,
Newcastle disease virus-, vesicular stomatitis virus- or herpes
simplex virus type 1-infected IRF-5 deficient mice have a
significant decrease in the induction levels of serum type I IFN
[3,4]. The virus-mediated type I IFN production is also partially
impaired in hematopoietic cells from IRF-5 deficient mice in vitro
[3]. Interestingly, normal type I IFN induction was observed in
mouse embryonic fibroblasts (MEFs) from IRF-5 deficient mice by
these viruses [3]. Paun et al. also reported that TLR9, but not
TLR3/4-mediated induction of type I IFN transcription, is
dependent on IRF-5 in dendritic cells [4].
IRF family members have been implicated as critical transcrip-
tion factors that function in cell growth regulation and
hematopoietic differentiation [14]. The expression of IRF-5 is
induced by viral infection through type I IFN signaling or by DNA
damage through activated p53. As a direct p53 target gene, IRF-5
also inhibits the growth of tumor cells both in vitro and in vivo
[9,15]. IRF-5 can also inhibit B-cell lymphoma tumor growth and
sensitizes p53-deficient tumors to DNA damage-induced apoptosis
and cell death [6,9,15]. Indeed, IRF-5 deficient MEFs showed a
similar phenotype to p53 deficient MEFs in DNA damage-induced
apoptosis, indicating that IRF-5 is essential to the apoptotic
response [3]. Barnes et al. reported that IRF-5 mediated growth
inhibition is associated with a p53-independent G2-M cell cycle
arrest and with the stimulation of multiple cell cycle regulatory and
proapoptotic genes including Bak, caspase 8, Bax, and p21 [15]. In
contrast, the study from Taniguchi’s group indicates that the
induction of p21 gene and the induction of cell cycle arrest
normally occur in IRF-5 deficient cells. They suggest that IRF-5 is
selectively involved in apoptosis but not in cell cycle arrest [3].
In this study, we identified a G202C (position relative to start
codon) missense mutation (Ala68Pro) in DNA binding domain of
IRF-5 (IRF-5(P68) in tumor or transform B and T cell lines and
peripheral blood from chronic lymphocytic leukemia (CLL) and
adult T-cell leukemia/lymphoma (ATL) patients. The IRF-5 (P68)
functions as a dominant negative molecule through interacting
with wildtype IRF-5, and leading to the inhibition of IRF-5 DNA
binding and transactivation activity. It will be of great interest to
examine the status of IRF-5 mutation in human cancers and the
role of this mutation on cell growth and apoptosis.
Materials and Methods
Ethics Statement
This study was approved by the Research Ethics Committee of
the SMBD-Jewish General Hospital (Federalwide Assurance
Number: 0796). Four patients with a diagnosis of B-CLL followed
at the Jewish General Hospital of Montreal were recruited in the
study after informed consent.
Plasmid constructions
Plasmids encoding GFP-IRF-5 (variant 1), Flag-IRF-5 (variant
1), Flag-IRF-5(4D) (variant 1), Myc-IRF-5 (variant 1), IRF-3(1-
133)/pGEX-4T-2, IRF-7(1-150)/pGEX-4T-2 and pRLTK were
described previously [10,16]. Human IRF-5P68 cDNA (variant 1)
was amplified by RT-PCR from Namalwa B-cell line and cloned
into myc pcDNA3.1/Zeo (Myc-IRF-5P68) and pEGFP-C1 (GFP-
IRF-5P68). GFP-IRF-5 pMSCV puro and GFP-IRF-5P68 pmscv
puro were generated by cloning the AgeI-BamHI fragment (filled
in with Klenow enzyme) from GFP-IRF-5 and GFP-IRF-5P68
into the BglII site (filled in with Klenow enzyme) of the pMSCV
puro vector (Clontech). IRF-5(1-130)/pGEX-4T-2 and IRF-5P68
(1-130)/pGEX-4T-2 were generated by PCR and cloned into
pGEX-4T-2 vector. The IL12p40-pGL3 was kindly gifted by Dr.
Keiko Ozato (NICHD, Bethesda, MD, USA).
Generation of stable cell lines and immunoblot analysis
Infectious retroparticles encoding either IRF-5P68 fused with
GFP or GFP alone were generated with 293-GP2 packaging cell
(Clontech, Mountain View, CA) and concentrated retroparticles
were used to gene modify RAW264.7 or human embryonic kidney
(HEK)293 cells. The monoclonal cell lines were selected by 4 ug/
ml of puromycine in RPMI 1640 (Wisent Inc.) supplemented with
10% fetal bovine serum, sodium pyruvate and antibiotics. To
determine the expression of the transgenes, equivalent amounts of
whole cell extract (20 mg) were subjected to SDS-polyacrylamide
gel electrophoresis (PAGE) with 10% polyacrylamide. After
electrophoresis, proteins were transferred to a Hybond transfer
membrane (Amersham) in a buffer containing 30 mM Tris,
200 mM glycine, and 20% methanol for 1 h. The membrane was
blocked by incubation in phosphate-buffered saline (PBS)
containing 5% dried milk for 1 h and then probed with anti-
GFP antibody (Roche) in 5% milk-PBS at a dilution of 1:2000.
These incubations were done at 4uC overnight or at room
temperature for 1 h. After three 10-min washes with PBS, the
membrane was reacted with a peroxidase-conjugated secondary
goat ant-mouse antibody (Amersham Corp.) at a dilution of
1:5000. The reaction was then vsualized with an enhanced
chemiluminescence detection system as recommended by the
manufacturer (Amersham).
DNA Sequencing
Peripheral blood lymphocyte samples from ATL patients and
normal donors were obtained from Dr Nazli Azimi (NCI,
Bethesda, MD, USA). Total RNA was isolated from PBMCs
obtained from either patients or healthy donors using the
QIAGEN RNeasy MiniKit. The total RNA from T cell lines
(CEM, Jukart) and B cell lines (Namalwa, Mc-KAR, BJAB and
BC-3) were kindly gifted by John Hiscott’s lab. Those total RNAs
were then subjected to reverse transcription using SuperScript II,
RNAseH
2 reverse transcriptase (Invitrogen) according to manu-
facturer’s instructions. The cDNAs either from reverse transcrip-
tion or cDNA library were amplified by PCR. The products were
then digested with Eco RI/Bam HI and cloned into pBluescript KS
(+). Plasmid DNA were isolated from individual clone and
subjected to sequence analysis. The primers for PCR were:
59GATCGAATTCCTCTGCCATGAACCAGTCCA39 and
59GATGGATCCGACCTCGTAGATCTTGTAGG39.
Protein expression and purification
The glutathione S-transferase (GST)-IRF-3, GST-IRF-5, GST-
IRF-5P68 and GST-IRF-7 fusion proteins were expressed and
isolated from E.coli DH5a following a 3 h induction with 1 mM
IPTG (Pharmacia) at 37uC. Bacterial extracts in PBS containing
1% Triton X-100 were incubated with glutathione sepharose
beads (Pharmacia) for 20 min at room temperature. After washed
three times with PBS, the fusion proteins were eluted with 15 mM
GSH in PBS.
Electromobility shift assay (EMSA)
Whole cell extracts were prepared 24 h after transfection with
expression plasmids. Cells were washed with phosphate buffered
saline (PBS) and lysed in 10 mM Tris-Cl (pH 8.0), 60 mM KCL,
IRF-5 Dominant Negative Mutant
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sulfonyl fluoride (PMSF), leupeptin (10 mg/ml), pepstatin (10 mg/
ml), aprotinin (10 mg/ml), chymostatin (0.5 mg/ml), and 0.25 mM
microcystin. Equivalent amounts of whole-cell extract (20 mg) or
various amounts of recombinant proteins were assayed for IRF-3,
IRF-5, IRF-5P68 and IRF-7 binding by gel shift analysis using a
32P-labled double-stranded oligonucleotide corresponding to the
interferon stimulated response element (ISRE) region of the
ISG15 promoter (59GATCGGAAAGGGAAACCGAAACT-
GAAGCC39). The binding mixture (20 ml) contained 10 mM
Tris-HCl (pH 7.5), 1 mM EDTA, 50 mM NaCl, 2 mM DTT, 5%
glycerol, 0.5% NP-40, 10 mg/ml of BSA, and 62.5 mg/ml of
poly(dI-dC) was added to reduce non-specific binding. After
20 min of incubation with the probe, extracts were loaded on a
5% polyacrylamide gel (60:1 cross-link) prepared in 0.5 X TBE.
After 2 h electrophoresis at 200 to 250 V, the gel was dried and
exposed to Kodak film at 270uC overnight. To demonstrate the
specificity of protein-DNA complex formation, either a 100-fold
molar excess of unlabled oligonucleotide or anti-Flag antibody




Transfections for luciferase assay were carried out in either
HEK293 cells or RAW264.7 cells. Subconfluent 293 cells were
transiently co-transfected with 50 ng of pRLTK reporter (Renilla
luciferase for internal control), 100 ng of pGL-3 reporter (firefly
luciferase, experimental reporter) and IRF-5, IRF-5P68 and
MyD88 by calcium phosphate co-precipitation method.
RAW264.7 cells seeded on 6-well plates were transfected with
100 ng of pRLTK reporter, 200 ng of pGL-3 reporter and IRF-5,
IRF-5P68 and MyD88 by using lipofectamine 2000
TM according
to the manufacturer’s instructions (Invitrogen). The reporter
plasmid was IL12p40 pGL-3 reporter gene. The total amounts
of DNA were kept constant by supplementation with an empty
vector (pcDNA3.1). At 24 h after transfection, the reporter gene
activities were measured by dual-luciferase reporter assay,
according to the manufacturer’s instructions (Promega).
Analysis of protein-protein interactions
HEK293 cells were transfected with expression plasmids.
Whole-cell extracts (300 mg) were prepared from transfected cells
and were incubated for 1 h at 4uC with 1 mg anti-Flag (M2;
Sigma-Aldrich) or anti-GFP (Roche) crosslinked to 100 ml protein
A/G PLUS-Agarose (Santa Cruz Biotechnology). Precipitants
were washed five times with lysis buffer and proteins were eluted
by boiling the beads for 3 min in 16SDS sample buffer. Eluted
proteins or 5% of the input whole cell extracts were separated by
10% SDS-PAGE. After electrophoresis, proteins were transferred
for 1 h to Hybond transfer membrances (Amersham) in a buffer
containing 30 mM Tris, 200 mM glycine and 20% (vol/vol)
methanol. Membranes were blocked by incubation for 1h in PBS
containing 5% (wt/vol) dried milk and then were probed with anti-
GFP, anti-Myc (9E10; Sigma-Aldrich) or anti-Flag, each at a
concentration of 1 ug/ml. Immunocomplexes were detected with
a chemiluminescence-based system (ECL; Amersham).
RT-PCR
Total RNA ( mg), isolated from monoclonal RAW264.7 cells
stably carrying GFP-IRF-5P68 or GFP using the QIAGEN
RNeasy MiniKit, was subjected to reverse transcription using
SuperScript II, RNAseH
2 reverse transcriptase (Invitrogen)
according to manufacturer’s instructions. The primers for IL6,
FLICE-inhibitory protein (FLIP) and IKBA were described in [17]
and GAPDH in [18]. The primers for IL12p40 were:
59- TTATGTTGTAGAGGTGGACTGG-39 and 59-
TTTCTTTGCACCAGCCATGAGC-39. One microliters of the
obtained cDNA was then amplified by PCR using Taq polymerase
(Amersham) as per manufacturer’s instructions. PCR conditions
were as follows for all primers: 94uC for 3 min, cycles: 94uC for
45 sec, 56uC for 45 sec, and 72uC for 1 min, 22–30 times
depending on optimal product detection, 72uC for 7 min. PCR
samples were then resolved in a 2% agarose gel and visualized by
Ethidium Bromide staining under UV light.
Enzyme-linked immunosorbent assay (ELISA)
Monoclonal RAW264.7 cells stably carrying GFP-IRF-5P68 or
GFP were mock treated (-) or treated with LPS (Sigma-Aldrich),
R837 or CpG ODN 1826 (Invivogen) for 24 h. IL6 and IL12p40
were measured by ELISA according to the manufacturer’s
instructions (PBL biomedical laboratories and R&D system,
respectively).
Results
Characterization of an IRF-5 mutant
IRF-5 is predominantly expressed in lymphoid cells such as T
cells, B cells, monocytes and macrophages [7,19]. While cloning
the human IRF-5 gene from a T cell cDNA library, we found a
G202C missense mutation that resulted in an Ala 68 Pro mutated
form of IRF-5 (referred to as IRF-5P68). To confirm the existence
of this mutant, we sequenced the IRF-5 cDNA amplified from a
Human T-cell leukemia virus type 1-infected T cell cDNA library
and an EBV-infected B cell cDNA library, respectively. As shown
in Table 1, the mutation was detected in both cDNA libraries and
the ratio of mutation was significant. We then isolated total RNAs
from a number of transformed T cell lines and B cell lines and
performed sequencing. The same mutation was identified in both
T cell lines (CEM and Jurkat) and B cell lines (Namalwa, Mc-
KAR, BJAB and BC-3). Interestingly, both virus-infected and non-
infected cell lines carried this mutation. These results raised the
possibility that this mutation is associated with some malignant
diseases, and unlikely derived from viral infection.
To further characterize the link between this mutation and
leukemic diseases, we sequenced the RNA samples obtained from
peripheral blood monocytes (PBMC) of patients suffering from
adult T-cell leukemia/lymphoma (ATL) and chronic lymphocytic
leukemia (CLL) and healthy donors as a control. The pathogenesis
of ATL results from HTLV-1 infection, while the pathogenesis of
CLL is not relevant to viral infection. As shown in Table 2, both
ATL and CLL patients carried this mutant, but healthy donors
not. This reveals that the IRF-5 mutation is probably linked to
ATL or CLL.
IRF-5P68 does not possess DNA binding activity
Like other IRF family members such as IRF-3 and IRF-7, IRF-
5 is also characterized as a trans-activator, which contains an N-
terminal DNA-binding domain and a C-terminal trans-activation
domain. Given that the mutation site occurs within the N-terminal
DNA-binding domain of IRF-5, we thus adopted bioinformatics
analysis. As shown in Fig. 1A, the mutation is located in the
flanking site of consensus sequence of IRF family member. We
therefore hypothesized that the point mutation may ablate its
DNA-binding activity. To test this hypothesis, we generated
glutathione S-transferase (GST) tagged recombinant N-terminal
DNA-binding domain of IRF-5 (referred to as GST-IRF-5), IRF-
5P68 (referred to as GST-IRF-5P68), IRF-3 (referred to as GST-
IRF-3) and IRF-7 (referred to as GST-IRF-7), respectively. The
IRF-5 Dominant Negative Mutant
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blue staining assay (Fig. 1B), and then subjected to electropheresis
mobility shift assay (EMSA). The GST-IRF-3, GST-IRF-5 and
GST-IRF-7 formed protein-DNA complex with the IFN-stimu-
lated response element (ISRE) in a dose-dependent manner. In
contrast, the formation of protein-DNA complex between GST-
IRF-5P68 and ISRE was not detected (Fig. 1C). These data
indicated that this missense mutation abrogates the DNA-binding
activity of IRF-5P68.
It is reported that in unstimulated cells IRF-5 predominantly
resides in the cytoplasm, and dynamically shuttles between nucleus
and cytoplasm. To investigate whether this point mutation
changes IRF-5 subcellular localization, wild type and point-
mutated form of IRF-5 were linked to GFP, stably tansfected into
HEK293 cells and RAW264.7 cells (mouse leukemic monocyte
macrophage cell line), and examined for leptomycin B (LMB)-
induced changes in subcellular localization. Like its counterpart
IRF-5 wild type, the major proportion of IRF-5P68 localized in
the cytoplasm of resting cells (data not shown). Treatment with
LMB, a CRM1 inhibitor, resulted in predominant nuclear
accumulation of IRF-5P68. These results suggest that this point
mutation does not markedly alter IRF-5P68 protein localization in
comparison with wild-type IRF-5 in resting cells.
IRF-5P68 inhibits IRF-5-mediated transactivation activity
IRF-5, as a transactivator, is a central mediator in the regulation
of proinflammatory cytokines, such as TNF-a, IL6 and IL12p40.
To examine the involvement of IRF-5P68 in the IRF-5-mediated
transactivation activity, we measured expression of luciferase
reporter gene driven by the IL12p40 promoter (IL12p40-luc) in
HEK293 and RAW264.7 cells. As shown in Fig. 2A, in both cell
lines, the IL12p40 promoter activity was effectively induced by
wild type IRF-5, but not IRF-5P68. Unexpectedly, the induction
of IL12p40 promoter activity by wild type IRF-5 was markedly
decreased with the increasing amounts of IRF-5P68 expression
(Fig. 2B). These findings suggest that IRF-5P68 might negatively
regulate IRF-5 transactivation activity.
Because IRF-5 was characterized as a downstream component
of TLR-MyD88- TNF receptor-associated factor (TRAF) 6
signalling, we next investigated whether the expression of IRF-
5P68 interferes with MyD88-mediated IRF-5 activation. As shown
in Fig. 2C, the IL12p40 promoter activity induced by MyD88 was
markedly suppressed by IRF-5P68 in a dose-dependent manner.
These results indicate that IRF-5P68 might participate in the
modulation of TLR-signalling.
IRF-5P68 interacts with wild-type IRF-5 and inhibited IRF-
5 DNA binding activity
IRF family members such as IRF-3, IRF-5 and IRF-7 can form
either homo-or hetero-dimers. Dimerization is critical for the
regulation of their activity [20]. These findings suggest that the
IRF-5P68 may modulate wild type IRF-5 activity through
intermolecular interactions between IRF-5P68 and wild type
IRF-5. To test this possibility, we expressed GFP-tagged IRF-5P68
together with Flag-tagged IRF-5 in HEK293 cells and performed
coimmunoprecipitation assay. As shown in Fig. 3A, GFP-tagged
IRF-5P68 was coimmunoprecipitated with Flag-tagged IRF-5, and
vice versa, Flag-tagged IRF-5 was coimmunoprecipitated with
GFP-IRF-5P68. To elucidate the possibility that binding of IRF-
5P68 to wild type IRF-5 blocks IRF-5 DNA binding activity, we
expressed Flag-tagged IRF-5 and Myc-tagged IRF-5P68 either
alone or together into HEK293 cells, and then subjected to
electrophoresis mobility-shift assay. As shown in Fig. 3B, Flag-
tagged IRF-5 alone but not Myc-IRF-5P68 bound to ISRE DNA
probe. This observation is consistent with previous data showing
that GST-IRF-5 bound to ISRE whereas IRF-5P68 did not.
Intriguingly, when coexpressed with Myc-IRF-5P68, the DNA-
binding activity of Flag-IRF-5 was strikingly compromised. These
observations indicate that IRF-5P68 can dimerize with wild type
IRF-5 and inhibit IRF-5 DNA-binding activity.
Because the IRF-5 mutant can interact with wild type IRF-5, it
should compete with wild-type IRF-5 for dimerization so as to
Table 1. Identification of Ala to Pro mutation in residue 68 of
IRF-5 from cDNA library and cell lines.
Source A68 (WT) P68(mutation) Mutation (%)
cDNA library
HTLV-1 infected T cell line 6 9 60
EBV infected B cell line 4 8 67
Tc e l l
CEM 6 8 57
Jurkat 5 6 55
Bc e l l
Namalwa 7 7 50
Mc-KAR 13 5 28
BJAB 10 9 47
BC-3 3 6 66
IRF-5 cDNA was PCR amplified from cDNA library or RT-PCR amplified with RNA
isolated from indicated cell lines and cloned into Bluescript vector. Frequency of
mutation was determined by DNA sequencing from plasmid DNA isolated from
each sample.
doi:10.1371/journal.pone.0005500.t001
Table 2. Identification of Ala to Pro mutation in residue 68 of
IRF-5 from peripheral blood of ALL/CLL patients.
Source A68 (WT) P68(mutation) Mutation (%)
Control
11 3 0 0
21 5 0 0
31 1 0 0
41 2 0 0
51 2 0 0
ATL
11 2 0 0
21 6 8 3 3
31 0 2 1 6
41 1 0 0
58 0 0
CLL
19 2 1 1
23 8 7 2
38 1 1 1
41 0 0 0
IRF-5 cDNA was PCR amplified from peripheral blood of healthy donors or ALL/
CLL patients and cloned into Bluescript vector. Frequency of mutation was
determined by DNA sequencing from plasmid DNA isolated from each sample.
doi:10.1371/journal.pone.0005500.t002
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members. (B) Coomassie staining of recombinant GST-tagged N-terminal IRF-3, IRF-5, IRF-5P68 and IRF-7. (C) EMSA of recombinant protein from a
incubated with a
32P-labeled probe corresponding to the ISRE motif from the promoter of the gene encoding the ubiquitin-like modifier ISG15. (C)
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possibility, we expressed fixed amounts of the Flag-tagged IRF-5
and Myc-tagged IRF-5 together with increasing amounts of GFP-
tagged IRF-5P68 into HEK293 cells and monitored IRF-5
dimerization by coimmunoprecipitation analysis. As shown in
Fig. 3C, IRF-5P68 inhibited IRF-5 dimerization in a dose-
dependent manner. These data suggest that IRF-5P68 interferes
with the formation of IRF-5 homodimer.
Figure 2. IRF-5P68 negatively regulates wild type IRF-5 transactivation activity. (A) HEK293 cells were transfected with pRLTK control
plasmid (50 ng), IL12p40-luc reporter plasmid (100 ng) and IRF-5-expressing plasmid (200 ng) together with an increase amount of IRF-5P68
expression plasmid (0, 40, 200 and 1000 ng) as indicated. Immunoblot analysis of whole cell lysates prepared for luciferase assay was showed (right).
(B) RAW264.7 cells were trasfected with pRLTK control plasmid (100ng), IL12p40-luc reporter plasmid (200 ng) and IRF-5-expressing plasmid (400 ng)
together with an increase amount of IRF-5P68 expression plasmid (0, 80, 400 and 2000 ng) as indicated. Immunoblot analysis of whole cell lysates
prepared for luciferase assay was showed (right). (C) RAW264.7 cells were trasfected with pRLTK control plasmid (100ng), IL12p40-luc reporter
plasmid (200 ng), MyD88- and IRF-5-expressing plasmid (300 ng) together with an increase amount of IRF-5P68 expression plasmid (0, 300, 900 and
1800 ng) as indicated. Immunoblot analysis of whole cell lysates prepared for luciferase assay was showed (right). In all transfections, the pcDNA3
vector was added to bring the total plasmid to the same amount. Luciferase activity was analyzed at 24-h post-transfection by the Dual-Luciferase
Reporter assay as described by the manufacturer (Promega). Relative luciferase activity was measured as-fold activation (relative to the basal level of
reporter gene in the presence of pcDNA3 vector after normalization with co-transfected RLU activity); values are mean 6 S.D. for three experiments.
doi:10.1371/journal.pone.0005500.g002
Representative green fluorescence images of living cells stably expressing IRF-5 and IRF-5P68 fused to GFP (top). The subcellular localization of the
GFP-IRF-5 and GFP-IRF-5P68 was analyzed in untreated and leptomycin B-treated HEK 293 and RAW 264.7 cells. GFP fluorescence was analyzed in
living cells with an Olympus BX51 fluorescence microscope using a X 40 objective. Bottom, immunoblot analysis is of GFP-IRF-5 and GFP-IRF-5P68
expression, and the expression of GFP alone as a control.
doi:10.1371/journal.pone.0005500.g001
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To examine the physiological function of IRF-5P68 in TLR-
IRF-5 signalling, we measured the TLR-induced expression of
endogenous IL12p40 and IL6 genes in RAW264.7 cells. To do so,
we generated RAW264.7 cell lines stably expressing GFP or GFP-
tagged IRF-5P68 and then stimulated the cells with TLR4 ligand
LPS, TLR7 ligand R837 or TLR9 ligand CpG ODN1668. RT-
PCR analysis revealed that TLR-ligand-induced expression of
IL12p40 and IL6 was abrogated in IRF-5P68 expressing cells
(Fig. 4A–C), whereas, for other genes, such as IKBA and FLIP, for
which IRF-5 was not required for mRNA induction, the mRNA
induction levels, in response to TLR7-ligand stimuli, remained the
same as those in control RAW264.7 cell lines (Fig. 4D). Because
the latter genes depend on NF-kB transcription factor, our results
revealed that the TLR-NF-kB signalling pathway was not affected
by IRF-5P68, at least under our experimental conditions.
We next measured TLR-ligand induced production of IL12p40
and IL6 by enzyme-linked immunosorbent assay. As shown in
Fig. 5, the IRF-5P68 expressing RAW264.7 cells produced much
less IL12p40 and IL6 in response to TLR4, TLR7 and TLR9-
ligand induction than did control RAW264.7 cell lines. These
Figure 3. IRF-5P68 interacts with wild-type IRF-5 and inhibits IRF-5 DNA binding activity. (A) HEK293 cells were transfected with
expression plasmids as indicated above the lanes. At 24 h post-transfection, Flag-tagged or GFP-tagged proteins were immunoprecipitated,
separated by SDS-PAGE and probed with indicated antibodies. Whole cell extracts (WCE) were also separated SDS-PAGE and probed with antibodies
as indicated. (B) HEK293 cells were transfected with expression plasmids as indicated (IRF-5WT: Flag-tagged; IRF-5P68: Myc-tagged). EMSA was
performed with whole cell extracts (30 mg) derived from transfected HEK293 cells and
32P-labelled probe corresponds to the ISRE of the ISG-15 gene
(left). Immunoblot analysis of whole cell extracts prepared for EMSA was showed (right). (C) HEK293 cells were transfected with expression plasmids
as indicated above the lanes. At 24 h post-transfection, Flag-tagged proteins were immunoprecipitated, separated by SDS-PAGE and probed with
indicated antibodies. Whole cell extracts (WCE) were also separated SDS-PAGE and probed with antibodies as indicated.
doi:10.1371/journal.pone.0005500.g003
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negative regulator by specifically targeting IRF-5.
Discussion
In this study, we have characterized a mutated form of IRF-5 in
tumor or transformed B and T cell lines and in PBMCs derived
from patients suffering from ATL or CLL. This is the first report
linking IRF-5 mutation to certain malignant diseases, although
previous studies using genetic methods have associated IRF-5 to
the development of autoimmune diseases such as systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA). Our study
demonstrates that this mutation dominant-negatively regulates the
transactivation activity of wild type IRF-5 through formation of
IRF-5-IRF-5P68 heterodimers.
Recently, the crystal structure analysis of IRF-1 and IRF-2
reveal that IRF DNA-binding domain consists of three a-helices,
three long loops and four stranded anti-parallel b-sheets (Fig. 1)
[21]. Given that this structure resembles the winged helix-turn-
helix (HTH)-containing DNA-binding motif and its mode of
protein-DNA interaction is distinct from that of other HTH-
containing proteins, the IRFs are therefore characterized as a
novel HTH-containing super-family member [22]. Both IRF-1
and IRF-2 use the third a-helix to contact the major groove of the
Figure 4. Mutated form of IRF-5 (P68) represses TLR-mediated IL6 and IL12 P40 induction. RT-PCR of transcripts encoding IL6 (IL6), IL12
P40 (IL12P40), FLIP (FLIP), IkBa (IKBA) or GAPDH (encoding glyceraldehyde phosphate dehydrogenase (loading control); GAPDH) in RAW264.7 cells
transduced with retroviral vector encoding GFP, GFP-IRF-5(wt) or GFP-IRF-5p68 and treated (time, above lanes) with TLR4 ligand LPS (A), TLR7 ligand
R837 (B and d) or TLR9 ligand ODN (C). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0005500.g004
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loops and the a–helices to contact the adjacent DNA sequence.
The secondary structure of IRF-5 DNA-binding domain is similar
to that of IRF-1 and IRF-2 [21,22,23], suggesting that IRF-5 may
utilize a similar model to recognize the similar DNA sequences. In
our study, the characterized mutation site of IRF-5 is positioned in
the flanking site of the fourth tryptophan within the N-terminal
DNA-binding domain, which is conserved among IRF family
members and is harboured by the second a-helix. The functional
analysis by EMSA and luciferase assay further shows that IRF-
5P68 completely loses its DNA-binding and transactivating
activities. Although the structural alteration derived from the
missense point mutation eradicates the DNA binding activity of
IRF-5P68, it does not remarkably alter other protein properties
because this mutant like its wild type predominantly localizes in
the cytosol and dynamically shuttles between cytoplasm and
nucleus in resting cells.
Human genome analysis shows that the mutation site of IRF-
5P68 is located within Exon 3 adjacent to its 59 end in the region
of chromosome 7q32.1. Based on this information, we consulted
the NCBI database for Single Nucleotide Polymorphorisms
(SNPs). Unexpectedly, no SNPs in relation to this mutation site
are presented in the database. We then sequenced the Exon 3 of
IRF-5 gene using the genomic DNA isolated from previously
described cell lines and PBMCs obtained from CLL patients
carrying the mutated transcripts. Intriguingly, the mutation is
undetectable at the genomic DNA level (Table S1), which
suggests that the point mutation does not result from SNPs. To
explore the molecular mechanism of this mutagenesis further, we
employed the Restriction Fragment Length Polymorphorism
(RFLP) method by southern-blot assay. By using Exon 3 DNA
sequence as probe, a roughly 10 kb fragment was unexpectedly
detected in the genomic DNA extracted from Jurkat cell line,
which carries IRF-5 mutant transcripts, but not in MT4 cell line
Figure 5. Mutated form of IRF-5 (P68) represses LPS- and R873-mediated IL6 and IL12 P40 production. ELISA of IL6 or IL12 P40 in
RAW264.7 cells transduced with retroviral vector encoding GFP (vector) or GFP-IRF-5P68 (P68) and then ‘mock-stimulated’ (control) or stimulated with
TLR4 ligand LPS (A), TLR7 ligand R837 (B and D) or TLR9 ligand ODN (C). Data represent the mean 6 s.d. of three experiments.
doi:10.1371/journal.pone.0005500.g005
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RFLP analysis by checking enzymatic cutting sites of IRF-5
pseudogene, located in chromosome 8q22.1 (pseudogene.org ID:
239282), was unable to give rise to a 10 kb fragment. These results
indicate that the novel 10 kb fragment may not come from IRF-5
pseudogene but from IRF-5 gene amplification or chromosomal
recombination. It will be of great interest to determine whether the
IRF-5P68 mutation is associated with IRF-5 gene amplification or
rearrangement. It has been demonstrated that RNA editing
enzymes are also involved in mRNA point mutation [24]. The
RNA editing enzymes consists of the adenosine deaminases that
act on RNA (ADAR) family and the apolipoprotein B editing
catalytic polypeptide (APOBEC) family [25,26,27], but none of
them is reported to participate in G to C mRNA editing,
suggesting that the IRF-5 mutation we found is unlikely caused by
RNA editing.
Mutagenesis resulting in functional ablation of tumor suppressor
genes is a molecular mechanism common in malignant cells to
circumvent tightly controlled proliferative and survival system of
mammalians. It has been well documented that the frequent loses
of copies of Rb, especially p53 genes in CLL contribute to disease
progression, poor response to chemotherapy and poor prognostic
outcome [28]. irf-5 has been characterized as a tumor suppressor
gene and the growth inhibition mediated by IRF-5 is underlined in
a manner independent on p53 [15]. IRF-5 sensitizes p53-deficient
tumors to DNA damage-induced apoptosis and cell death [6]. In
addition, DNA damaging reagents can induce IRF-5 nuclear
accumulation, and irf-5 is also associated with the stimulation of
multiple cell cycle regulatory and proapoptotic genes [3]. These
observations indicate that mutation of irf-5 might be a molecular
mechanism employed by malignant cells to achieve the capacity of
survival or proliferation, and protecting themselves from killing by
chemotherapeutical treatment. On the other hand, the discovery
of an IRF-5 mutation lacking transactivation activity in ATL and
CLL may unveil a clue that the transactivation activity of IRF-5
might play an essential role in its function as a turmor suppressor.
Furthermore, weak immunogenicity of CLL cells may contrib-
ute to disease progression and inhibit the effectiveness of
immunotherapies [29,30]. It has been demonstrated that in
response to TLR7 activation, CLL cells increase costimulatory
molecular expression, produce inflammatory cytokines and
become more sensitive to killing by cytotoxic effectors [31].
Similarly, costimulation of CLL with TLR9-ligand CpG-ODN
and CD40-ligand CD40LF strongly increases in inflammatory
cytokine production and costimulatory molecular expression [32].
IRF-5 is a key player of TLR7/TLR9 signalling and is involved in
tumor cell growth and apoptosis. The important role of IRF-5 in
cell growth control is also emphasized in naı ¨ve primary B cells, in
which the Epstein-Barr virus induces the negative regulators of
IRF-5, the IRF-5v12 and IRF-4 [17], to neutralize TLR7 ligand-
induced cell growth inhibition [33]. Thus, the mutation of IRF-5
in CLL patients may affect disease progression and immunother-
apies through compromising IRF-5 transactivation activity.
In addition, recent in vivo studies utilizing mice deficient in the
Irf-5 gene have also characterized IRF-5 as a key component of
death-receptor-induced apoptosis in a cell-type-specific manner
[34]. IRF-5 is implicated in a stage of Fas (CD95/APO-1/
TNFRSF6) signalling upstream of caspase 8 and c-jun N-terminal
kinase (JNK). However, the activation of Fas receptor is not
capable of inducing IRF-5 nuclear accumulation. These observa-
tions therefore raise an important issue of whether IRF-5 functions
as an adaptor protein or a transcriptional activator in death-
receptor-induced apoptotic signalling.
To summarize, although IRF-5P68 mutation is present in
malignant hematopoietic diseases, ATL and CLL, the link
between the novel IRF-5 point mutation to clinical implications,
such as pathogenesis, drug resistance and prognosis, remains to be
clarified. Future studies will focus on the effect of this mutation on
immuno- and chemo-therapies to improve clinical diagnosis and
treatment, and therefore predict the outcomes for patients
suffering from hematopoietic malignant diseases such as ATL
and CLL. In addition, understanding the molecular mechanism of
this mutation may shed light on the development of novel tumor-
suppression-gene mutation mechanisms in malignant diseases.
Supporting Information
Table S1 Detection of Ala to Pro mutation in residue 68 of IRF-
5 genome. IRF-5 exon 3 was PCR amplified from genomic DNA
isolated from indicated cell lines, peripheral blood from healthy
donors or CLL patients carrying IRF-5P68 transcript and cloned
into Bluescript vector. The mutation of IRF-5 was determined by
DNA sequencing from plasmid DNA isolated from each sample.
Found at: doi:10.1371/journal.pone.0005500.s001 (0.06 MB
DOC)
Figure S1 Southern bloting analysis of HindIII/XbaI-digested-
genomic DNA from Jurkat (1) and MT4 (2) cell lines using the
exon 3 of IRF-5 as probe.10 mg of genomic DNA isolated from
either Jurkat (carring an IRF-5P68 mutation) or MT4 (without
IRF-5 mutation) cell lines were digested with Hind III and Xba I,
separated by 0.8% agarose gel electrophoresis, transferred to
nitrocellulose membranes by upward capillary transfer in 20x
saline-sodium citrate (SSC) overnight, and then hybridized to the
radiolabeled whole exon 3 of human irf-5 isoform a (48%
formamide, 10% dextran sulfate, 5x SSC, 1x Denhardt’s solution,
and 100 mg/ml salmon sperm DNA) at 42uC overnight. The
membranes were washed in 2x SSC containing 0.1% SDS for
15 min at room temperature with rotation and then in 0.1% SSC
containing 0.1% SDS for another 15 min at 60uC. The
autoradiograms were prepared using Kodak BioMax film at
280uC with intensifying screens.
Found at: doi:10.1371/journal.pone.0005500.s002 (3.52 MB TIF)
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